POINT Biopharma (PNT) Next Generation Radioligands November 2022

POINT Biopharma Global Inc. presents its next-generation radioligand platform for oncology applications, including late-stage programs PNT2002 for prostate cancer and PNT2003 for neuroendocrine tumors. The company highlights operational manufacturing capabilities, strong cash position of $292M, and a $260M upfront licensing collaboration with Lantheus Holdings with potential milestone payments up to $1.8B through 2025.